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The European Association for Predictive, Preventive and Personalised Medicine (EPMA) considers acute problems in
medical sciences as well as the quality and management of medical services challenging health care systems in
Europe and worldwide. This actuality has motivated the representatives of EPMA to comment on the efforts in
promoting an integrative approach based on multidisciplinary expertise to advance health care-related research and
management. The current paper provides a global overview of the problems related to medical services: pandemic
scenario in the progression of common non-communicable diseases, delayed interventional approaches of reactive
medicine, poor economy of health care systems, lack of specialised educational programmes, problematic ethical
aspects of several treatments as well as inadequate communication among professional groups and policymakers. In
the form of individual paragraphs, the article presents a consolidated position of PPPM professionals towards the new
European programme ‘Horizon 2020’ providing the long-lasting instruments for scientific and technological progress in
medical services and health care-related programmes. In the author's opinion, Horizon 2020 provides unlimited room
for research and implementation in Predictive, Preventive and Personalised Medicine. However, the overall success
of the programme strongly depends on the effective communication and consolidation of professionals relevant
for PPPM as well as the communication quality with policymakers. Smart political decision is the prerequisite of the
effective PPPM implementation in the health care sector. This position is focused on the patients' needs, innovative
medical sciences, optimal health and disease management, expert recommendations for the relevant medical fields
and optimal solutions which have a potential to advance health care services if the long-term strategies were to be
effectively implemented as proposed here.
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as the medicine of the future: EPMA vision
Current health care: What is behind the issue?
For many acute and chronic disorders, the current health
care outcomes are considered as being inadequate: global
figures cry for preventive measures and personalised
treatments. In fact, severe chronic pathologies such as
cardiovascular disorders, diabetes and cancer are treated* Correspondence: Olga.Golubnitschaja@ukb.uni-bonn.de
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article, unless otherwise stated.after onset of the disease, frequently at near-end stages.
Pessimistic prognosis considers pandemic scenario for
type 2 diabetes mellitus, neurodegenerative disorders
and some types of cancer over the next 10–20 years
followed by the economic disaster of health care systems
in a global scale.Advanced health care tailored to the person: What is
beyond the issue?
Advanced health care promotes the paradigm change
from delayed interventional to predictive medicine tailored
to the person, from reactive to preventive medicine
and from disease to wellness. The innovative Predictive,Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Book series Advances in Predictive, Preventive and
Personalised Medicine. This is the specialised didactic material for
Universities, medical centres and specialised international
programmes [1].
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as the focal point of efforts in health care aimed at curbing
the prevalence of both communicable and non-commu-
nicable diseases such as diabetes, cardiovascular diseases,
chronic respiratory diseases, cancer and dental pathologies.
The cost-effective management of diseases and the critical
role of PPPM in modernisation of health care have
been acknowledged as priorities by global and regional
organisations and health-related institutions such as
the Organisation of United Nations, the European Union
and the National Institutes of Health.
Why integrative medical approach by PPPM as the
medicine of the future?
PPPM is the new integrative concept in health care sector
that enables to predict individual predisposition before on-
set of the disease, to provide targeted preventive measures
and create personalised treatment algorithms tailored
to the person. The expected outcomes are conducive to
more effective population screening, prevention early in
childhood, identification of persons at risk, stratification
of patients for the optimal therapy planning, prediction
and reduction of adverse drug-drug or drug-disease
interactions relying on emerging technologies, such as
pharmacogenetics, pathology-specific molecular patters,
subcellular imaging, disease modelling and individual
patient profiles. Integrative approach by PPPM is consid-
ered as the medicine of the future. Being at the forefront
of the global efforts, the European Association for Predict-
ive, Preventive and Personalised Medicine (EPMA, http://
www.epmanet.eu/) promotes the integrative concept of
PPPM among health care stakeholders, governmental in-
stitutions, educators, funding bodies, patient organisations
and in the public domain.
Multidisciplinary aspects of advanced bio/medical
approaches and innovative technologies overviewed by
EPMA/Springer book series
For the paradigm shift from delayed reactive to Predictive,
Preventive and Personalised Medicine, a new culture should
be created in communication between individual profes-
sional domains, between doctor and patient, as well as
in communication with individual social (sub)groups and
patient cohorts. Considering this long-term mission, a
particular role is dedicated to the multidisciplinary and
trans-domain education in PPPM requiring innovative
design of specialised didactic materials. In this context,
an integration of a spectrum of professional groups into
the overall concept of PPPM is a particular advantage of
the EPMA/Springer book series Advances in Predictive,
Preventive and Personalised Medicine—the didactic ma-
terial specialised in PPPM (see Figure 1). Expert rec-
ommendations focus on the cost-effective management
tailored to the person in health and disease. Innovativestrategies are considered for standardisation of health care
services. New guidelines are proposed for medical ethics,
treatment of rare diseases, innovative approaches to
early and predictive diagnostics, patient stratification
and targeted prevention in healthy individuals, persons at
risk, individual patient groups, subpopulations, institutions,
health care economy and marketing.
The additional bibliographic details of the series are the
following:
Series Editor: Olga Golubnitschaja
Released volumes:
– Healthcare Overview: New Perspectives
(Ed: V. Costigliola) ISBN 978-94-007-4602-2
– New Strategies to Advance Pre/Diabetes Care:
Integrative Approach by PPPM (Ed: M. Mozaffari)
ISBN 978-94-007-5970-1
– Neurodegenerative Diseases: Integrative PPPM
Approach as the Medicine of the Future
(Ed: S. Mandel) ISBN 978-94-007-5865-0
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Potentially Applicable in Personalised Treatments
(Ed: J. Coelho) ISBN 978-94-007-6009-7
Volumes releasing in 2014–2015:
– Rare Diseases: Integrative PPPM Approach as the
Medicine of the Future (Ed: M. Özgüç)
– Individualised Medicine: Ethical, economical and
historical perspectives (Ed: T. Fischer, M. Langanke,
P. Marschall);
– Preventive and Predictive Genetics: Towards
Personalised Medicine (Ed: G. Grech, I. Grossman)
– Circulating nucleic acids in early diagnosis,
prognosis and treatment monitoring: an
introduction (Ed: P. Gahan).
PPPM in Horizon 2020—short overview of the
history and preparatory steps: the facts speak
for themselves
Basic EPMA event, November 13, 2008
The juristic protocol has been signed—the Association is
born now. Its objectives are to create and promote the
concepts and practical realisation of Predictive, Preventive
and Personalised Medicine.
The founder members of the Directorate are shown in
Figure 2.Figure 2 Founder members of the Directorate. (from right to left)
First line: V. Costigliola (President), O. Golubnitschaja (Secretary General).
Second line: K. Krapfenbauer (Vice President responsible for European
affairs), M. Kapalla (Director responsible for contacts with industry), S.
Mandel (Vice President responsible for associated countries and
contacts apart from Europe).The global concepts of Predictive, Preventive and
Personalised Medicine—the medicine of the future
The following important aspects are covered in the book
Predictive Diagnostics and Personalized Treatment: Dream
or Reality, edited by O. Golubnitschaja published in 2009
(see Figure 3):
 Predictive Medicine as the new philosophy in
health care.
 Advanced technologies in Predictive and
Personalised Medicine.
 Prediction in non-diseased population.
 Targeted preventive measures.
 Prediction of secondary complications.
 Prediction of drug sensitivity and drug response.
 Personalised patient treatment.
 Optimised therapy planning.
 Role of information systems.
 Economic aspects.
 Role of insurance.
 Ethics.Figure 3 Predictive Diagnostics and Personalized Treatment:
Dream or Reality. Editor: O. Golubnitschaja, ‘Nova Science
Publishers’, New York, June 2009.
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Secretary of UNO
The first meeting of EPMA representatives with the Vice
Secretary of UNO took place in Geneva on December 8,
2009 (see Figure 4).Publication of specialised issue of The EPMA Journal on
global PPPM concepts for stakeholders
Global PPPM concepts for stakeholders (researchers,
health care providers, patient organisations, policymakers)
have been published by the specialised issue of The EPMA
Journal in March 2010 [2] (Figure 5).Organisation of a series of preparatory workshops to
create Horizon 2020 by EU Commission
In the year 2010, the European Commission has orga-
nised a series of preparatory workshops in order to
create Horizon 2020 (Figure 6). Several EPMA experts
have been invited to chair, talk and create protocols at
the sessions [3].Final conference in preparation of Horizon 2020 by the
EU Commission
The finalising conference in the preparation of Horizon
2020 by the EU Commission took place in Brussels on
May 12–13, 2011 (see Figure 7) [4]. Among the invited
speakers wereFigure 4 EPMA goes global in consensus with United Nations.
Left to right: EPMA President, V. Costigliola, UNO Vice Secretary
General S. Ordzhonikidze, EPMA Secretary General O. Golubnitschaja.– Prof. Dr. R. Danesi, The National EPMA
Representative in Italy.
– Prof. Dr. C. Swanton, The member of the National
EPMA BOARD in UK.
– Prof. Dr. O. Golubnitschaja, Editor-in-Chief and
Secretary General of EPMA.
EPMA World Congress
In September 2011, EPMA World Congress took place in
Bonn, Germany to discuss and create long-term strategies
in PPPM (see Figure 8).
Release of the White Paper 2012, The EPMA Journal
Consequently, EPMA has released its fundamental docu-
ment—White Paper 2012 of the European Association for
Predictive, Preventive and Personalised Medicine, The
EPMA Journal in 2012, Open Access [5].
EPMA Summit
Finally, the EPMA Summit took place in the EU Par-
liament to discuss PPPM-relevant programmes in
Horizon 2020, professional consolidation and communi-
cation with policymakers [6] (see Figure 9).
Release of Horizon 2020—Work Programme 2014–2015
On December 11, 2013 the EU Commission has released
Horizon 2020—Work Programme 2014–2015 ‘Health,
demographic change and well-being’ [7] (Figure 10).
Horizon 2020 as the European long-term strategy
in medicine: targets, domains, structure and overall
meaning of the programme
Horizon 2020 is the biggest EU Research and Innovation
programme ever with the budget almost EUR 80 billion of
funding for the next 7 years (2014–2020)—see Figure 11 [8].
Horizon 2020 is the financial instrument implementing
the Innovation Union Europe 2020 [9], a flagship initiative
aimed at securing Europe's global competitiveness.
Horizon 2020 follows achievements in the previous
programme, 7th Framework Programme for Research and
Technological Development (2007 to 2013). Horizon 2020
differs in the structure from FP7, by coupling research
and innovation, aiming to achieve this with its emphasis
on excellent science, industrial leadership and tackling
societal challenges (see Figure 12). The goal is to ensure
that Europe produces world-class science, removes barriers
to innovation and makes it easier for the public and private
sectors to work together in delivering innovation.
What is new?
Horizon combines three previously separate programmes:
Framework programme (FP), Competitiveness and Innovation
Framework Programme (CIP), and the European Institute





















































Figure 5 Global PPPM concepts for stakeholders, The EPMA Journal 2010, Springer.
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are the following:
 Simplification through a simpler programme
architecture (structure)
 Simplified access for all companies,
universities, institutes in all EU countries
and beyond
 Single set of rules with a simplified reimbursement
procedure.
 Single point of access for participants.Figure 6 A series of the preparatory workshops by the EU-Commissio
*OMICS in Personalised Medicine (workshop to explore the role of *omics
aspects; Biomarkers for patient stratification; Opportunities and challenges fHorizon 2020 is open to everyone, with a simple struc-
ture that reduces red tape and time so participants can
focus on what is really important. This approach makes
sure new projects get off the ground quickly and achieve
results faster.
The EU Framework Programme for Research and
Innovation will be complemented by further measures
to complete and further develop the European Research
Area. These measures will aim at breaking down barriers
to create a genuine single market for knowledge, research
and innovation [8].n in Brussels in order to create Horizon 2020. (from left to right)
in the development of personalised medicine); Clinical trials/regulatory
or European health care.
Figure 7 European event of high importance, May 2011.
Figure 9 Brussels, September 2013: EPMA Summit in the
EU Parliament.
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Horizon 2020 will focus resources on three distinct, yet
mutually reinforcing, priorities, where there is clear
Union added value. These priorities correspond to
those of Europe 2020 and the Innovation Union (see
Figure 13).Figure 8 Bonn, Germany, September 2011. Over 40 countries
have been represented at the EPMA World Congress in
PPPM.(1) Excellent Science – This will raise the level of
excellence in Europe's science base and ensure a
steady stream of world-class research to secure
Europe's long-term competitiveness. It will support
the best ideas, develop talent within Europe, provide
researchers with access to priority research
infrastructure, and make Europe an attractive location
for the world's best researchers. This will
 Support the most talented and creative
individuals and their teams to carry out frontier
research of the highest quality by building on the
success of the European Research Council.
 Fund collaborative research to open up new and
promising fields of research and innovation
through support for Future and Emerging
Technologies (FET).
 Provide researchers with excellent training and
career development opportunities through the
Marie Skłodowska-Curie actions ('Marie Curie
actions').
 Ensure that Europe has world-class research
infrastructures (including eInfrastructures)
accessible to all researchers in Europe and
beyond.Figure 10 Horizon 2020 as the long-term European programme
to support research and the innovation.
Figure 11 Diagram illustrates the budget distribution in Horizon 2020.
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Europe a more attractive location to invest in
research and innovation (including eco-innovation),
by promoting activities where businesses set the
agenda. It will provide major investment in key
industrial technologies, maximise the growth potential
of European companies by providing them with
adequate levels of finance and help innovative small
and medium enterprises (SMEs) to grow into
world-leading companies. This will
 Build leadership in enabling and industrial
technologies, with dedicated support for
informatics and communicating technologies
(ICT), nanotechnologies, advanced materials,
biotechnology, advanced manufacturing and
processing, and space, while also providing
support for cross-cutting actions to capture theFigure 12 Horizon 2020 is focused on excellence in science, industrial leadaccumulated benefits from combining several
Key Enabling Technologies.
 Facilitate access to risk finance.
 Provide Union wide support for innovation in
SMEs.(3)Societal Challenges – This reflects the policy
priorities of the Europe 2020 strategy and addresses
major concerns shared by citizens in Europe and
elsewhere. A challenge-based approach will bring to-
gether resources and knowledge across different
fields, technologies and disciplines, including social
sciences and the humanities. This will cover activities
from research to market with a new focus on
innovation-related activities, such as piloting,
demonstration, test beds, and support for public
procurement and market uptake. It will includeership and tackling societal challenges.
Figure 13 Priorities of Horizon 2020 that correspond to those of Europe 2020 and Innovation Union.
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Innovation Partnerships. Funding will be focussed on
the following challenges:
 Health, demographic change and well-being.
 Food security, sustainable agriculture, marine and
maritime research and the bioeconomy.
 Secure, clean and efficient energy.
 Smart, green and integrated transport.
 Climate action, resource efficiency and raw
materials.
 Inclusive, innovative and secure societies.
The EIT will play an important role by combining ex-
cellent research, education and innovation, thus integrat-
ing the knowledge triangle. The EIT will do so primarily
through the Knowledge and Innovation Communities
(KICs). In addition, it will ensure that experiences are
shared beyond the KICs through targeted dissemination
and knowledge-sharing measures.
The Joint Research Centre's activities will be an integral
part of Horizon 2020, providing robust, evidence-based
support to Union policies. This will be driven by customer
needs complemented by forward-looking activities.
Horizon 2020 will be a 7-year programme and there
may be significant shifts in the broader economic and
policy context as the programme progresses. Ensuring
Horizon 2020's continued relevance will therefore also
require to adjust priorities and resources, as and whennecessary. As such, flexibility clauses have been included
in the proposal in this respect.
The implementation of Horizon 2020 will also take a
strategic approach to programming of research and
innovation, using joint actions and modes of governance
aligning closely with policy development yet cutting across
the boundaries of traditional sectoral policies. This will
be based on sound evidence, analysis and foresight, with
progress measured against a robust set of indicators.
As regards the funding of research activities involving
human embryonic stem cells, the Horizon 2020 legislative
package is fully in line with the approach supported by the
European Parliament and the Council upon their adoption
of the FP7 legislation, as set out in the Commission's
statement of 2006 (OJ L412 of 30 December 2006).
International cooperation
International cooperation with the third countries is
necessary to address effectively many specific objectives
defined in Horizon 2020. This is the case in particular for
all the societal challenges addressed by Horizon 2020,
which need to be tackled at the global level. International
cooperation is also essential for frontier and basic research
in order to capture the benefits from emerging science
and technology opportunities. Promoting the international
mobility of researchers and innovation staff is crucial for
enhancing this global cooperation. Activities at the
international level are equally important to enhance the
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take-up and trade of novel technologies, for instance
through the development of worldwide standards and
guidelines and by promoting the acceptance and deploy-
ment of European solutions outside Europe.
The aim of international cooperation in Horizon 2020
will be to strengthen the Union's excellence and attract-
iveness in research, to tackle global challenges jointly
and to support the Union's external policies. The focus
of international cooperation in Horizon 2020 will be on
cooperation with three major country groupings:
(1) Industrialised and emerging economies.
(2) Enlargement and neighbourhood countries.
(3) Enlargement of developing countries.
Where appropriate, Horizon 2020 will promote co-
operation at the regional or multilateral level. Inter-
national cooperation in research and innovation is a key
aspect of the Union's global commitments and has an
important role to play in the Union's partnership with
developing countries, which are often disproportionately
affected by global challenges. This cooperation will promote
inclusive growth and progressing towards the achievement
of the Millennium Development Goals and other goals
agreed in the framework of international sustainable
development.
Horizon 2020 will continue with the principle of general
openness, while encouraging reciprocal access to third
country programmes. In addition, a range of targeted
actions will be implemented taking a strategic approach
to international cooperation on the basis of common
interest and mutual benefit and promoting coordination
and synergies with Member State activities. Dedicated
support measures to assist the strategic approach and
the process of priority setting are included in the ‘Inclusive,
innovative and secure societies' challenge.
Horizon 2020 basic documents
 COM/2011/0808 Horizon 2020—The Framework
Programme for Research and Innovation—
Communication from the Commission.
 COM/2011/0809 Proposal for a Regulation of the
European Parliament and Council establishing
Horizon 2020—the Framework Programme for
Research and Innovation (2014–2020).
 COM/2011/0810 Proposal for a Regulation of the
European Parliament and Council laying down the
rules for the participation and dissemination in
Horizon 2020.
 COM/2011/0811 Proposal for a Council Decision
establishing the Specific Programme implementing
Horizon 2020. COM/2011/0812 Proposal for a Council Regulation
on the research and training programme of the
European Atomic Energy Community (2014–2018)
complementing Horizon 2020.
 COM/2011/0817 Proposal for a Regulation of the
European Parliament and of the Council amending
Regulation (EC) No 294/2008 establishing the
European Institute of Innovation and Technology
(EIT).
 COM/2011/0822 Proposal for a Decision of the
European Parliament and of the Council on the
Strategic Innovation Agenda of the European Institute
of Innovation and Technology (EIT): the contribution
of the EIT to a more innovative Europe.
New European programme as the optimal
instrument to promote the global leadership in
medical innovation, excellent science and
advanced health care
Horizon 2020—Societal challenge Health, demographic
change and well-being
‘…to improve the lifelong health and well-being of all.’
Health, demographic change and well-being is the first
and financially significantly supported societal challenge
(see Figure 14).
Lifelong health and well-being for all, high-quality and
economically sustainable health and care systems are the
key words of Horizon 2020 and will make a major contri-
bution to Europe 2020 strategy.
Europe will be for this 7-year period facing several
challenges:
 Great demographic change: the number of
Europeans aged over 65 is expected to nearly double
from 85 million in 2008 to 151 million by 2060, and
those over 80 to rise from 22 to 61 million in the
same period.
 Chronic diseases such as cardiovascular disease
(CVD), cancer, diabetes, neurological and mental
health disorders, overweight and obesity and various
functional limitations are major health and societal
problems for the future. In Europe, CVD annually
accounts for more than 2 million deaths and costs
the economy more than EUR 192 billion while
cancer accounts for a quarter of all deaths and is
the number one cause of death in people aged
45–64. Over 27 million people in the EU suffer
from diabetes and the total cost of brain disorders
(including, but not limited to those affecting
mental health) has been estimated at EUR 800
billion.
 The research and development of new drugs and
vaccines are becoming more expensive and less
effective.
Figure 14 Societal challenges prioritised within the Horizon 2020.
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levels separately; the coordinated European
approach will enhance to eliminate fragmentation
and duplicity in research, will contribute to
addressing these challenges and deliver better health
and well-being for all European citizens.
 The innovative approach depends on excellence in
research to improve our fundamental understanding
of health, disease, disability, development and ageing
(including of life expectancy), and on the seamless
and widespread translation of the resulting and
existing knowledge into innovative and effective
products, strategies, interventions and services.
 As a new progressive feature is the implementation of
ICT techniques, technologies and tools. These include
the development of long-term cohorts and the conduct
of clinical trials, the clinical use of ‘omics’ or the
development of ICT and their applications in health
care practice, notably eHealth and mHealth.
 Big data means that biomedical research and health
care bring every minute new information, data/data
sets about an individual, cohort, population. Big data
is difficult to collect, store, save, share and work with.
 The requirements of specific populations are also
best addressed in an integrated manner, in the
development of stratified and/or personalised
medicine, in the treatment of rare diseases, and in
providing assisted and independent living solutions.
 Coordinated European effort will contribute to the
ongoing development of the European Research
Area (ERA). It will interface with activities
developed in the context of the Health for Growth
Programme and the European Innovation
Partnership on Active and Health Ageing.Philosophy of health care is changing
Health care is changing
 From illness to health.
 From treatment to prevention and early diagnostics.
 From approach one-fits-all to personalised medicine.
Effective health promotion prevents disease, improves
well-being and is cost effective. Health promotion and dis-
ease prevention depend on an understanding of the deter-
minants of health, on effective preventive tools, such as
vaccines, on effective health and disease surveillance and
preparedness, and on effective screening programmes.
An increasing disease and disability especially in an
ageing population places further demands on health and
care sectors. If effective health and care is to be maintained
for all ages, efforts are required to improve decision-
making in prevention and treatment provision, to identify
and support the dissemination of best practice in the
health and care sectors and to support integrated care and
the wide uptake of technological, organisational and
social innovations empowering, in particular, older per-
sons as well as disabled persons to remain active and
independent. Doing so will contribute to increasing
and lengthening the duration of their physical, social
and mental well-being.
Horizon 2020 provides unlimited room for research
and implementation in Predictive, Preventive and
Personalised Medicine
Integrated, sustainable, citizen-centred care (this topic is
considered within Horizon 2020)
As a consequence of the accumulating clinical data and
knowledge about the epidemiology and pathological
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and mortality, we are currently reconsidering our view of
the origins and progression of cardiovascular, oncologic
and neurodegenerative diseases. The majority of these
pathologies are of chronic nature: they progress from
precursor lesions over one or even several decades of
life; therefore, it is often too late for effective therapeutic
intervention. An excellent example is the pandemic of
type 2 diabetes mellitus witnessed in the European Union.
In most industrialised countries and countries with
large populations, the permanently growing cohort of
diabetics creates a serious health care problem and a
dramatic health economic burden. The estimate for dia-
betes prevalence in the years 2025–2030 is half a billion
patients worldwide (see Figure 15).
Moreover, the contemporary onset of the dominant
type 2 diabetes was already observed in subpopulations of
teenagers. Severe complications secondary to early onset
of diabetes mellitus, such as retinopathy, nephropathy,
silent ischaemia, dementia and cancer (Figure 16), soon
may lead to collapsing health care systems.
Clearly, the multidimensional features of diabetes mellitus
(DM) require a systematic approach, with the best coor-
dinated involvement of collaborative, multidisciplinary
inter/national teams of clinicians, scientists and health
care professionals across the spectrum of the medical
field. The 3-dimensional trans-disciplinary coordinating
and networking action across the professional fields
might be the best instrument within the Horizon 2020
in order to respond to the listed challenges as schemat-
ically demonstrated in Figure 17. This integrative well-
coordinated medical approach utilises the innovation
by predictive diagnostics as the basis for concomitant
targeted prevention, patient profiling as the basis for
individualised treatment algorithms and medical ap-
proaches tailored to the patient. Creation of innovative
‘proof-of-principle’ for health and disease management
followed by new guidelines in health care should createFigure 15 Worldwide prognosis of the DM pandemic. *Estimations as p
published in 2003–2008. Current prognosis is marked in red colour [10].a robust juristic and economic platform for advanced med-
ical services utilising the cost-effective models of risk assess-
ment followed by tailored treatments focussed on the
precursor stages of non-communicable chronic disease [11].
Understanding health, ageing and disease (this topic is
considered within Horizon 2020)
A number of molecular mechanisms have received con-
siderable attention in contributing to the understanding
of the pathogenesis underlying DM and its attendant
complications (see Figure 18). However, the complex
and intrusive nature of the disease means that the quest
(involving diverse scientific domains and disciplines)
must continue to better unravel contributing mecha-
nisms of initiation and progression of DM and its target
organ complications. This multidisciplinary paradigm is
essential to bridge the substantial gap between research
and clinical sectors, in a translational fashion. Identifi-
cation of pathogenic mechanisms, therapeutic targets
and biomarker sets to predict, prevent and personalise
treatment of DM patients is the central focus of such an
orchestration (Challenge/Action 1 ‘Networking of stake-
holders’, see Figure 17). These concepts create a feasible
and credible professional platform aimed at providing
proof-of-principle models for advanced health and disease
management.
Innovative treatments and technologies (this topic is
considered within Horizon 2020)
Optimal health care intervention is a cascade of events
functionally linked to each other and based on the in-
novative technologies that allow for individual predic-
tion, targeted prevention and treatments tailored to
the person. This innovation, before becoming successfully
applied in daily medical practice, should be carefully cre-
ated at the level of preparatory measures and individual
research steps moving from basic research to the clinical
implementation as summarised in Figure 19. Without theublished around the year 2000. **Stepwise worsening prognosis as
MANIFESTED DM followed by microcirculation disturbances
    retinopathy, nephropathy 
            vasculopathy, atherosclerosis  
                valvular calcificaltion & degeneration 
       shortened re-operation time of implanted bioprothesis
                         cardiomyopathy, silent infarcts, sudden death
                                polyneuropathy, neurological disorders
                                    cancer, extensive necrosis, “diabetic foot”
   poor life-quality and treatment outcomes 
      poor economy of Diabetes care 
     missing ethical standards  
Figure 16 Severe complications/comorbidities developed secondary to diabetes. From ‘upstream’ (up) to ‘downstream’ (bottom) in the
cascade of pathologic processes [10].
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within the nominated steps, a successful implementa-
tion of innovative treatments was rather illusive. This




















2010: 258 million 
2030: 439 million 
Increase: 54%
Figure 17 PPPM in pre/diabetes care. 3-Dimensional trans-domain coord
challenges 1, 2 and 3, respectively. CVD cardiovascular disease, NNND neuro
and oral pathologies, ID infectious diseases. DM affected regions: DM preval
corresponding percentage of increase.Improving diagnosis (this topic is considered within
Horizon 2020)
Perhaps the best example for this task represents the
cohort of individuals affected by birth asphyxia. Accord-






        
Action 2.
WORKING for research & disease
agement of collateral pathologies
OP         ID       Cancer
Primary level of 
expertise 
inating and networking action by the EPMA responding to the
logical, neuropsychiatric and neurodegenerative diseases, DOP dental
ence (million of patients) recorded in 2010 and predicted for 2030 with
Figure 18 Potential mechanisms for the increased risk of both degenerative processes and malignancies under stress condition. The
first part circled in green colour shows physiologic repair of damaged single cells. The second part circled in red colour demonstrates
pathophysiologic processes leading either to degenerative or malignant transformations [12].
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birth complication with the prevalence between 1 and 100
cases per 1,000 live births in diverse populations worldwide
(see Figure 20).
Secondary to perinatal (birth) asphyxia, a postnatal
















Figure 19 Moving from basic research to clinical implementation. Ess
technologies for early/predictive diagnostics and personalised treatments [is frequently observed being associated with either mild
or severe organ damage in asphyxiated newborns, both
leading to the development of chronic pathologies. The
severe insults often cause neurodegenerative diseases,
mental retardation and epilepsies manifested later in life.



















ential steps in creating the evidence-based platform for innovative
13].
Figure 20 Specialised screening programmes and targeted preventive measures. Specialised screening programmes and
targeted preventive measures are essential to be performed in newborns for timely protection against severe outcomes of perinatal
complications such as birth asphyxia. An example: the correlation of TAU-protein levels (see the diagram) found between brain
(mesencephalon, M) and blood samples and asphyxic newborns (A, PA) versus controls (C) allows the performance of minimally
invasive blood tests to determine the specific brain damage potentially leading to sever long-term outcomes such as tauopathies
(Alzheimer's disease and others) [14].
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but can also be associated with the development of
schizophrenia, lifelong functional psychotic syndromes and
damage and pathologies of other life-important organs
(the kidney, heart, vascular system and others). In some
particular cases, it is difficult to discriminate between mild
and severe asphyxia: advanced methodology to improve
diagnosis of birth asphyxia and prediction of individual
short- and long-term outcomes obligatorily needs to be
developed. The complete overview to the central biological
processes affected by perinatal asphyxia is schematically
presented in Figure 21. The figure provides compre-
hensive information about the metabolic particularities
of the hypoxic processes, potential impairments and
short- versus long-term outcomes which can be ex-
pected with individually manifested grade of severity.
Hypoxic-ischaemic encephalopathy, CNS damage, epi-
lepsy, nephropathy, cardiomyopathy, vascular pathologies,
senescence, diabetes mellitus, cancer, neurodegenerative
diseases, morbidity and mortality and tissue remodelling
all belong to individual short- and long-term outcomesof birth asphyxia [14]. Specialised issues of The EPMA
Journal have been dedicated to the ‘PPPM in Diabetes’,
‘PPPM in Neurodegenerative Diseases’, ‘PPPM in Can-
cer’, ‘PPPM in Cardiovascular Diseases’, ‘PPPM in Body
Culture and Sport Medicine’, ‘PPPM in Health care
Overview’, where the articles overview the innovative
technologies of predictive diagnostics, targeted preven-
tion measures, desirable personalisation of medical care,
individual prediction, targeted prevention and persona-
lised treatments before a manifestation of lifelong chronic
pathologies.
Effective health promotion, disease prevention,
preparedness and screening (this topic is considered
within Horizon 2020)
Paradigm change from delayed reactive medicine to pre-
dictive diagnostics followed by targeted prevention before
manifestation of pathology presents innovative concept
for advanced health care. Pre-selection of healthy but
pathology-predisposed individuals represents the primary
task in the overall action. One of the best examples might
Figure 21 Metabolic particularities, impairments and individual outcomes by perinatal asphyxia. PPPM predictive, preventive and
personalised medicine. Adapted from [14].
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who, however, represent a group of risk strongly predis-
posed to several pathologies due to vascular dysregulation
with concomitantly shifted gene expression and other
syndrome-specific alterations at molecular and subcellular
levels as it is demonstrated in Figure 22. Since vasospasticA
B
Figure 22 Proteomics imaging of blood biomarkers (ex vivo identifica
glaucoma (NTG). (A) Top: The pathology-specific protein-cluster is comple
(B) Bottom: The marked protein SSP2602 is highly up-regulated in both NT
leukocytes of controls—healthy individuals without vasospasm [18].syndrome is a frequent phenomenon in adolescence and
young adults, this makes the task of prediction and tar-
geted prevention of downstream-related pathologies
particularly attractive from several points of view including
economical aspects [15-17]. Protein patterns in circulat-
ing leukocytes demonstrate clear similarities betweention in circulating leukocytes) specific for normal-tension
tely suppressed in both NTG and vasospasm in contrast to controls.
G and vasospasm; this protein normally does not express by circulating
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Moreover, protein clusters can be considered to develop
the biomarker sets for predictive imaging of healthy
vasospastic individuals predisposed to glaucoma as
shown in Figure 22. Subcellular imaging and ‘gene hunting’
investigations provide further evidence for vasospasm
as predisposition to glaucoma. However, development
of some other related pathologies cannot be excluded.
Predictive molecular profiling in the blood can specify
individual predisposition for effective prevention with low
costs. Alternatively to *omics technologies, diagnostic and
prognostic approaches utilising circulating nucleic acids in
plasma and serum, urine, saliva, and tear fluid can be
of great importance. New guidelines are essential to
regulate the field of non-invasive predictive technologies to
improve personalised treatment of healthy but pathology-
predisposed groups of risk. The instruments offered by
Horizon 2020 are essential to motivate both health care
providers and patients for participative medicine (active
cooperation between patient and physician) before man-
ifested pathologies.
Accelerated ageing or inadequate health care? Advancing
active and healthy ageing with utilising instruments of
Horizon 2020 (this topic is considered within Horizon 2020)
Current figures
Over 300 million diabetics frequently affected by poly-
neuropathy as secondary complication, 18 million patients
with Alzheimer's disease (also diagnosed as diabetes type
3), neurodegenerative eye diseases with leading causes of
blindness—diabetic retinopathy and estimated 70 million
glaucoma patients worldwide, millions of patients with
Parkinson's disease, multiple sclerosis, epilepsy, cerebral
palsy and dementia in the elderly—these are all the patient
cohorts with severe neurological disorders, who demon-
strate dramatically decreased life quality. Progressive neu-
rodegeneration is the common feature of multifactorial
physical and cognitive disability. Permanently increasing
numbers of those patients as well as dramatic disease-
related economical burden indicate that current education,
research and health care in this field are far from optimal
and should be corrected. Since neurodegeneration is a
chronic process, which begins long before the onset of
clinically diagnosed symptoms, currently there is an
evident lack of targeted prevention in any age-category
inchoate with early childhood, over adolescence until
late adulthood [19].
Optimistic versus pessimistic prognosis
This depends much on diagnostic, preventive and treat-
ment approaches which health care will preferably
adopt in the near future. Without innovation in health
care, neurodegenerative disorders can reach more than
30% of global disease burden until 2020. In contrast,effective utilisation of advanced early/predictive diag-
nostics, preventive and personalised medical approaches
could enable a significant portion of population to reach
the 100-year age limit remaining vibrant in excellent
physical and mental health as actively contributing mem-
bers of society. Specialised calls of Horizon 2020 aim at
solving the accumulated problems and promote active
and healthy ageing, early risk detection, mental well-
being within ageing populations, application of ICT
technologies for independent living with cognitive im-
pairments as well as robotics services within assisted
living environments.
Improving health information, data exploitation and
providing an evidence base for health policies and
regulation (this topic is considered within Horizon 2020)
Through the support of the Alexander von Humboldt
Foundation in the years 2012–2013, EPMA has performed
a specialised project focused on the collaboration among
PPPM-related professional groups and policymakers. This
project was aimed at identifying problems and deficits in
health care of common and pandemic chronic diseases
such as type 2 diabetes mellitus. Interviews performed
with experts from all countries of the European Union,
Israel, Russia and Turkey resulted in the conclusion that
one of the common deficits is a missing communication
and collaboration between individual professional groups
on one side and health care professionals and decision-
makers on the other side. Moreover, there are difficulties in
accessing national regulatory bodies to enhance the mes-
sage of patient-focused health care. This evidence demon-
strates that decisions in the health care sector are generally
made without consideration of accumulated professional
knowledge. This may explain the lack of sufficient efficacy
currently observed in health care systems.
In contrast, if well established, the collaboration with
governmental bodies may lead to the reconsideration
of current national and European guidelines for health
care-relevant research activities and medical services
both advanced by PPPM. There are following emerging
issues to be within the instruments and programmes of
Horizon 2020:
 Promoting research fields focused on the patient
needs
 Mandating a paradigm shift from reactive to
predictive and preventive medicine.
 Creating specialised state budgets to target
preventive measures against pandemic incidence of
non-communicable chronic diseases.
 Forcing an effective implementation of innovative
predictive diagnostics.
 Advancing bioinformatics to meet biomedical and
clinical needs.
Golubnitschaja et al. The EPMA Journal 2014, 5:6 Page 17 of 29
http://www.epmajournal.com/content/5/1/6 Facilitating digital representation of health data to
improve professional communication and optimise
diagnostic and treatment approaches.
 Introducing optimal medical records.
 Standardising predictive technologies for human
safety testing.
 Creating new educational programmes for
professionals to implement integrative medical
services in predictive, preventive and personalised
medicine.
 Creating educational measures to increase the
understanding of innovative diagnostic technologies
and targeted preventive measures in the general
population.
 Creating new economic models to motivate health
responsibility.
As health care is subject to national subsidiarity, there
are substantial variations in the level of provision in
different countries. However, corresponding standards
might be introduced at the European level to promote
inter-European mobility and to avoid economic discrepan-
cies and conflict of interest [20].
Comments on and ‘ready-to-go’ information about the
first calls released for 2014–2015
The most important features of SC1 especially for the
two open calls 2014, 2015 are the following: improving
health promotion and disease prevention; understanding
disease and improving diagnosis; developing effective
screening programmes and improving the assessment of
disease susceptibility; improving surveillance and pre-
paredness; developing better preventive vaccines; using
in silico medicine for improving disease management
and prediction; treating disease; transferring knowledge to
clinical practice and scalable innovation actions; better use
of health data; active ageing, independent and assisted
living; individual empowerment for self-management of
health; promotion of integrated care; improving scientific
tools and methods to support policy making and regu-
latory needs; optimising the efficiency and effective-
ness of health care systems and reducing inequalities
by evidence-based decision-making and dissemination of
best practice; and innovative technologies and approaches.
Work programme for 2014 and 2015 [21] (see also Tables 1
and 2) consists of seven thematic areas with 34 topics
for project proposals, ten coordination actions and other
activities:
1. Understanding health, ageing and disease.
PHC 1–2014: Understanding health, ageing and
disease: determinants, risk factors and pathways.
PHC 2–2015: Understanding diseases: systems
medicine.PHC 3–2015: Understanding common
mechanisms of diseases and their relevance in
comorbidities.
2. Effective health promotion, disease prevention,
preparedness and screening.
PHC 4–2015: Health promotion and disease
prevention: improved intersector cooperation for
environment- and health-based interventions.
PHC 5–2014: Health promotion and disease
prevention: translating omics into stratified
approaches.
PHC 6–2014: Evaluating existing screening and
prevention programmes.
PHC 7–2014: Improving the control of infectious
epidemics and foodborne outbreaks through rapid
identification of pathogens (see also societal
Challenge 2).
PHC 8–2014: Vaccine development for poverty-
related and neglected infectious diseases: tuberculosis.
PHC 9–2015: Vaccine development for
poverty-related and neglected infectious
diseases: HIV/AIDS.
3. Improving diagnosis.
PHC 10–2014: Development of new diagnostic
tools and technologies: in vitro devices, assays and
platforms.
PHC 11–2015: Development of new diagnostic
tools and technologies: in vivo medical imaging
technologies.
PHC 12–2014/2015: Clinical research for the
validation of biomarkers and/or diagnostic medical
devices.
4. Innovative treatments and technologies.
PHC 13–2014: New therapies for chronic
non-communicable diseases.
PHC 14–2015: New therapies for rare diseases.
PHC 15–2014/2015: Clinical research on
regenerative medicine.
PHC 16–2015: Tools and technologies for
advanced therapies.
PHC 17–2014: Comparing the effectiveness of
existing health care interventions in the elderly.
PHC 18–2015: Establishing effectiveness of health
care interventions in the paediatric population.
5. Advancing active and healthy ageing.
PHC 19–2014: Advancing active and healthy
ageing with ICT: service robotics within assisted
living environments.
PHC 20–2014: Advancing active and healthy
ageing with ICT: ICT solutions for independent
living with cognitive impairment.
PHC 21–2015: Advancing active and healthy
ageing with ICT: early risk detection and
intervention.
Table 1 Information about the calls released for thematic areas in 2014–2015: schedule, taken from [21]
Theme Stage/phase Stage/phase
PHC 1–2014 Stage 1—11th March 2014 at
1700 hours, Brussels time
Stage 2—19th August 2014 at








PHC 7–2014 Single stage—15th April 2014








PHC 12–2014/2015 Phase 1 Phase 2 Phase 1 Phase 2
18th June 2014 09th October 2014 {18th March 2015 17th June
2015 17th September 2015
16th December 2015}
{18th March 2015 17th June
2015 17th September 2015
16th December 2015}Open call cut-off dates 24th September 2014 17th December 2014
Open from 1st March 2014
for phase 1 and phase 2a
17th December 2014
Conditions for this call: Publication date 11 December 2013. Deadline(s) (2014): 11 March 2014 (stage 1 of two stage calls), 15 April 2014 (single stage call), 19 August
2014 (stage 2 of two stage calls), PHC 12–2014/2015 (as below). The Director General responsible may delay this deadline by up to 2 months. Any deadlines provided in
brackets are indicative and are subject to a separate financing decision for 2015. aThe Director General responsible may delay this date by up to 2 months.
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PHC 23–2014: Developing and comparing new
models for safe and efficient, prevention oriented
health and care systems:
PHC 24–2015: Piloting personalised medicine in
health and care systems.
PHC 25–2015: Advanced ICT systems and
services for Integrated Care.
PHC 26–2014: Self-management of health and
disease: citizen engagement and mHealth.
PHC 27–2015: Self-management of health and
disease and patient empowerment supported
by ICT.
PHC 28–2015: Self-management of health and
disease and decision support systems based on
predictive computer modelling used by the patient
him or herself.
PHC 29–2015: Public procurement of innovative
eHealth services.
7. Improving health information, data exploitation and
providing an evidence base for health policies and
regulation.
PHC 30–2015: Digital representation of health
data to improve disease diagnosis and treatment.PHC 31–2014: Foresight for health policy
development and regulation.
PHC 32–2014: Advancing bioinformatics to meet
biomedical and clinical needs.
PHC 33–2015: New approaches to improve
predictive human safety testing.
PHC 34–2014: eHealth interoperability.Coordination activities summarised in Tables 3 and 4
are the following:
HCO 1–2014: Support for the European Innovation
Partnership on Active and Healthy Ageing.
HCO 2–2014: Joint Programming: Coordination Action
for the Joint Programming Initiative (JPI) ‘More Years,
Better Lives—the Challenges and Opportunities of
Demographic Change’.
HCO 3–2015: Support for the European Reference
Networks: efficient network modelling and
validation.
HCO 4–2014: Support for international infectious
disease preparedness research.
HCO 5–2014: Global Alliance for Chronic Diseases:
prevention and treatment of type 2 diabetes.
Table 2 Information about calls released for thematic areas in 2014–2015: indicative budget for calls, taken from [21]
Theme 2014 2015 Stage
EUR million EUR million
PHC 1–2014 54.00 Two stage
PHC 2–2015 36.00 Two stage
PHC 3–2015 30.00 Two stage
PHC 4–2015 18.00 Two stage
PHC 5–2014 24.00 Two stage
PHC 6–2014 15.00 Two stage
PHC 7–2014 15.00 (with an additional 5.00
million from SC2)
Single stage and hearing
PHC 8–2014 25.00 Single stage and hearing
PHC 9–2015 21.00 Single stage and hearing
PHC 10–2014 48.00 Two stage
PHC 11–2015 47.00 Two stage
PHC 12–2014/2015 66.10, out of which 6.61 for phase
1, 58.17 for phase 2 and 1.32 for
mentoring and coaching support
and phase 3
45.00, out of which 4.50 for phase
1, 39.60 for phase 2 and 0.90 for
mentoring and coaching support
and phase 3
SME instrument
PHC 13–2014 60.00 Two stage
PHC 14–2015 60.00 Two stage
PHC 15–2014/2015 36.00 35.00 2014–one stage, one deadline
PHC 16–2015 36.00 Two stage
PHC 17–2014 48.00 Two stage
PHC 18–2015 26.00 Two stage
PHC 19–2014 24.60 Single stage
PHC 20–2014 10.00 Single stage
PHC 21–2015 21.00 Single stage
PHC 22–2015 17.00 Two stage
PHC 23–2014 30.00 Two stage
PHC 24–2015 30.00 Two stage
PHC 25–2015 20.00 Single stage
PHC 26–2014 59.60 Single stage
PHC 27–2015 15.00 Single stage
PHC 28–2015 20.00 Single stage
PHC 29–2015 10.00 Single stage
PHC 30–2015 20.00 Single stage
PHC 31–2014 6.00 Single stage
PHC 32–2014 24.00 Two stage
PHC 33–2015 30.00 Two stage
PHC 34–2014 4.00 Single stage
TOTAL 549.30 537.00
Indicative budget: EUR 549.30 million from the 2014 budget, of which EUR 5.00 million from the societal challenge ‘Food security, sustainable agriculture and
forestry, marine and maritime and inland water research and the bioeconomy’ and subject to the availability of the appropriations provided for in the draft
budget for 2014 after the adoption of the budget for 2014 by the budgetary authority or if the budget is not adopted as provided for in the system of provisional
twelfths. EUR 537.00 million from the 2015 budget (the budget amounts are indicative and will be subject to a separate financing decision to cover the amounts
to be allocated for 2015). Single stage for both phase 1 and phase 2. The budget available for phase 1 and phase 2 will be divided equally between each
cut-off date.
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Table 3 Full information about the calls dedicated to the
coordination measures, taken from [21]
Schedule











Conditions for this call: Publication date December 11, 2013. Deadline, 15 April
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2015 priority.
HCO 7–2014: ERA-NET: Establishing synergies
between the Joint Programming on Neurodegenerative
Diseases Research and Horizon 2020.
HCO 8–2014: ERA-NET: Aligning national/regional
translational cancer research programmes and activities.ble 4 Indicative budget, taken from [21]
2014 2015 Stage
EUR million EUR million
O 1–2014 2.00 Single stage
O 2–2014 2.00 Single stage
O 3–2015 2.00 Single stage
O 4–2015 3.00 Single stage
O 5–2014 9.00 Single stage
O 6–2015 12.00 Single stage
O 7–2014 5.00 Single stage
O 8–2014 5.00 Single stage
O 9–2014 5.00 Single stage
O 10–2014 5.00 Single stage
O 11–2015 5.00 Single stage
O 12–2015 5.00 Single stage
O 13–2015 5.00 Single stage
O 14–2014 1.00 Single stage
O 15–2014 1.00 Single stage
O 16–2014 2.00 Single stage
TAL 40.00 29.00
e EUR 40.00 million from the 2014 budget is subject to the availability of
e appropriations provided for in the draft budget for 2014 after the
option by the budgetary authority or if the budget is not adopted as
ovided for in the system of provisional twelfths. EUR 29.00 million from the
15 budget amounts is indicative and will be subject to a separate financing
cision to cover the amounts to be allocated for 2015.HCO 9–2014: ERA-NET: Systems medicine to address
clinical needs.
HCO 10–2014: ERA NET: Rare disease research
implementing IRDiRC objectives.
HCO 11–2015: ERA-NET: Collaboration and alignment
of national programmes and activities in the area of brain-
related diseases and disorders of the nervous system.
HCO 12–2015: ERA-NET: Antimicrobial resistance.
HCO 13–2015: ERA-NET: Cardiovascular disease.
HCO 14–2014: Bridging the divide in European health
research and innovation.
HCO 15–2014: Mobilisation and mutual learning
action plan.
HCO 16–2014: National Contact Points.
Other actions are also available:
HOA 1–2014/2015: Subscription fee: Human Frontier
Science Programme Organisation.
HOA 2–2014/2015: Tenders for programme
evaluation, studies and impact assessment and for
conferences, events and outreach activities.
HOA 3–2014/2015: Presidency events—eHealth.
HOA 4–2014/15: Independent experts assisting in
proposal evaluations and project reviews.
HOA 5–2014: Grant to the Global Alliance for Chronic
Diseases.
HOA 6–2014: Stem cell research outreach.
HOA 7–2015: eHealth Sectoral Inducement Prize.
HOA 8–2015: Inducement prize.
For getting all relevant information about the upcoming
call in Horizon 2020 SC1, every participant has to register
at PARTICIPANT PORTAL [22] then in main menu go
to FUNDING OPPORTUNITIES, in the central column
find SOCIETAL CHALLENGES and click on HEALTH,
DEMOGRAPHIC CHANGE AND WELLBEING, and
finally the newly opened screen is the page with all
information about the topics and for project proposal
submission [21].
EPMA strategies within Horizon 2020
Health care paradigm shift from delayed reactive to
Predictive, Preventive and Personalised Medicine:
innovation, scientific and technological excellence
For many acute and chronic disorders, the current health
care outcomes are considered as being inadequate [1,20].
Current health care practices essentially rely on the emer-
gence of signs and symptoms of human pathologies prior
to initiation of interventional modalities as illustrated
in Figure 23A. Consequently, long-term morbidity and
prognosis may often be poor but the associated costs
are extremely high and permanently increasing year-by-
year worldwide. Most impressive examples include the
A B
Figure 23 Health care approaches. Current health care approach (A) versus advanced health care approach (B). The advanced health care
approach considers a paradigm change from delayed interventional to predictive, preventive and personalised medicine as the robust platform
for optimal medical services; figure is taken from [23].
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disorders and some types of cancer, which, over the next
10–20 years, associated with the economic situation, could
spell disaster for health care systems on a global scale. A
desirable strategy is illustrated in Figure 23B. The major
premise of the advanced health care approach is the
paradigm change from reactive to predictive medicine,
from delayed to preventive and personalised medicine.
This requires the application of innovative biotechnologies
to predict human pathologies, the devising of appropriate
and timely preventive strategies and individualised treat-
ment planning.
Predictive and prognostic tests: why and how to realise in
medical practice
The following actualities motivate the introduction of
predictive and prognostic approaches into daily medical
services:
– Reactive disease care.
– Delayed intervention.
– Untargeted medication.
– Overdosed and poisoned patients.
– Low effectiveness of treatments.
Current deficits in medical services such as missing
toxicological examination of the prescribed medication
and ethically problematic delayed reactive and inadequate
treatments require new strategies for a targeted preven-
tion of diseases and negative side effects of treatments
[24]. Clinically validated predictive and prognostic tests
provide new perspectives on how to advance and person-
alise medical services.Accuracy, sensitivity and specificity of predictive and
prognostic tests are the premise of advanced health care.
There is the evident necessity to enable globally comparable
investigative, diagnostic and prognostic strategies to be re-
liably implemented. This requires regulatory oversight and
meaningful engagement with in vitro diagnostic providers.
The globalisation of markets and laboratory-related
business requires the comparability, or the unification,
of laboratory test values. The mobility of both patients
and health care professionals as well as the increasing
global data flow require such comparability [25]. Hence,
the unification of laboratory tests should be placed at the
top of the list of corresponding adapting measures.
In order to create a robust investigative platform,
the utilisation of appropriate predictive and prognostic
approaches should be mandated, which means an exten-
sive collaboration between relevant professional organisa-
tions on one side and policymakers on the other side
resulting in a well-organised promotion and widespread
application of the predictive medical care in health care
systems.
Multidisciplinary analytical expertise is essential for
optimal clinical decisions
Optimal clinical decisions result from a multidisciplin-
ary approach performed by specialists with complementary
analytical expertise. Therefore, the overall task is formu-
lated as the integrative medical approach of the multimodal
diagnostics, application of health- versus disease-specific
biomarker patterns, creation of individual patient profiles
and widespread medical records which altogether allow
for treatments tailored to the person [13]. Multimodal
diagnostics (i.e. deep, early and predictive diagnostics)
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of examination resulting in extended patient profiles and
medical records which obligate inclusion of an interview
with the patient, application of multidisciplinary question-
naires, medical imaging, in vitro diagnostics and accurate
evaluation of pathology-relevant and potential risk factors.
For laboratory diagnostics, it is highly recommended to
perform analysis at complementary levels and consider
stage-specific molecular patterns, such as DNA poly-
morphisms, transcriptional regulation, shifted protein
expression patterns, post-translational modification, stage-
specific subcellular imaging and altered activity of enzym-
atic complexes.
Consequent paradigm change in health care is the
reconsideration of competencies and responsibilities in
the laboratory-clinician interface
Shifting the role of laboratory medicine from the ‘passive
performing’ to the ‘active advising’ is the consequent
paradigm change in health care resulting from the
above-listed necessities and expected innovations. This
reconsideration of the laboratory-clinician interface
might significantly advance the quality of current medical
services, although the implementation of this approach
across countries should be adapted to local conditions.
Well-known motivating actualities for the reconsideration
are, for example, so-called within-individual variations
as well as grey-zone results, when individual laboratory
parameters range between ‘healthy’ and ‘unhealthy’ zones
and any interpretation is problematic for clinicians. There-
fore, recommendations by the laboratory tests/interpreta-
tions to assist clinical practice are essential [20,26]. This
assistance ranges from advising on the necessity for add-
itional tests to the consequent analysis of the fluctuating
targets. Additional tests should be considered from the
viewpoint of their reasonability, in order to reach an
accurate and realistic health-related data interpretation
for the individual. The analysis of dynamic changes of
the target is essential to evaluate potential health impacts
such as an individual predisposition to the disease and/or
a predictive diagnosis before a clinical manifestation of
symptoms. Laboratory value-added investigation and data
interpretation should be obligatory promoted to advance
functional relationship between laboratory medicine and
clinicians both as the responsible decision-makers [20,27].
Healthy ageing and solutions for independent living with
the long-term health impairments: demographic change
and societal challenges
Current trends in Europe demonstrate dramatic demo-
graphic shifts in favour of elderly subpopulations. With
type 2 diabetes mellitus, pandemic and its severe second-
ary complication such as stroke, 50% of people after
85 years of age are affected by Alzheimer's disease (alsodiagnosed as type 3 diabetes), neurodegenerative eye
diseases which are the leading causes of blindness, diabetic
retinopathy and estimated 70 million glaucoma patients
worldwide, and there are millions with Parkinson's disease,
multiple sclerosis, epilepsy and dementia in the elderly
[28]. Optimistic versus pessimistic prognosis depends
much on diagnostic, preventive and treatment approaches
which health care systems will preferably adopt in the near
future. Without innovation in health care, neurodegenera-
tive disorders can reach more than 30% of the global
disease burden until 2020. In contrast, effective utilisation
of advanced early/predictive diagnostics, preventive and
personalised medical approaches could enable a signifi-
cant portion of population to reach the 100-year age limit
remaining vibrant in excellent physical and mental health
as actively contributing members of society. These realities
require new strategies in medical services focused on
maintaining physical and mental health of ageing pop-
ulations. Further, to satisfy the needs of long-term
monitoring of chronically diseased patients with a po-
tential duration of some years to several decades of life,
a new generation of point-of-care monitoring devices is
required. These mobile health technologies must enable
self-monitoring, distanced monitoring and the remote
management of diseases of people for independent living
with health impairments.
Progressing from a ‘disease care’ to ‘health care’: ‘well-being’
concepts
The evident pandemic of common chronic diseases, the
consequences of a reactive approach and hence poor
economy of disease care as well as dramatic social and
ethical problems that result from delayed medical services
necessitate experts to reconsider the current paradigm of
reactive disease care in favour of health care. This means
that there is a mandated progressive implementation of a
new philosophy of the well-being concept tailored to the
person (age, gender, socio-economic status, individual pre-
dispositions, patient-specific profiles, etc.) as a spectrum
of personalised measures for professional care that pro-
motes the mental and physical health of an individual
[24]. Consequently, better individual outcomes are ex-
pected with respect to less morbidity, better quality of life
and improvement of both health economy and ethical
standards [20,29,30].
Forcing the practical application of health- versus
disease-specific biomarker patterns: industrial leadership
Current calculations demonstrate a long-term trend of
the dramatic crisis in the creation of clinically useful
molecular entities (biomarkers, drug targets, etc.). Further,
an innovation in in vitro diagnostic testing is hampered
by a lack of funding for studies aiming at the effective
validation of the clinical utility of novel biomarkers.
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time span between a discovery of new molecular targets,
creation of valid health- versus disease-specific bio-
marker patterns and their effective utilisation in daily
practice is the strategic point of highest priority [31].
Up to this point, expert recommendations have been
summarised in the EPMA White Paper in 2012 [5]. The
proposed measures include the following:
– Emerging technologies in population screening
(faster, more precise, cheaper).
– Set-up of pathology-specific biomarker patterns
instead of ineffective single molecules.
– Non- or minimally invasive diagnostic tools (saliva,
urea, tear fluid, blood samples).
– Effective promotion of validation studies.
– Transparent schemes for functional contacts
between researchers who discovered new targets
and implementing industrial partners.
– Dramatic improvements in national and
international patenting systems.
An effective implementation of the above-listed measures
may favour more flexible small- and middle-sized industrial
companies in the competitive process of PPPM-related
innovation.
Optimal organisation of biopreservation and biobanking
Well-organised biopreservation and biobanking is expected
to create a robust platform for the optimal set-up of health-
and disease-specific biomarker patterns and drug targets.
Therefore, ethically correct and technologically excellent
biopreservation and biobanking are central activities in the
field of PPPM. As it has been formulated in the EPMA
White Paper in 2012 [5], a list of essential requirements for
the optimal organisation of biopreservation and biobanking
should be functionally satisfied. Competencies should be
harmonised among the main stakeholders, namely patients,
scientific community and health care providers which
includes commercial companies interested in in vitro
diagnostics, development of biomarker patterns and novel
drug targets. However, currently, biobanking is facing
major viability challenges. As for individual types of bio-
logical material (tissue samples, blood samples, DNA,
RNA, proteins, metabolites, etc.), national laws vary for
local instructions and legal approaches and how samples
may be collected, stored, retrieved and tested. In plenty of
cases, this may be quite restrictive and incompatible with
rules that are legal for other countries. The analytical qual-
ity of collections is frequently compromised as the storage
condition for the samples is changing. Donation of sam-
ples to a biobank not only requires anonymity but also
strict control over record linkage and access. Sample
collections with a permission of specialised ethicalcommission should be hosted by viable academic units
and health facilities with a proven record of research
and should not be exploited for commercial gain but for
the common good. Disease-focused collections require
acquired samples to be retrospectively valid for a de-
velopment of novel biomarkers. Such biomarkers need
to have a demonstrated clinical utility prior to their intro-
duction in medical services. For a disease-specific bio-
banking, the disease needs to have been well characterised
for each patient, with immaculate record-keeping, to enable
to draw conclusions on the new markers. These critical
problems may be optimally solved by relevant profes-
sional groups with complementary expertise such as the
European Federation of Clinical Chemistry and Laboratory
Medicine, EPMA and ESBB followed by adequate deci-
sions of policymakers resulting in the creation of a ro-
bust juristic platform. An international biobanking, if
designed as being reliable for advanced health care ser-
vices, needs an adequate juristic platform that considers
the following interests of all parties involved in the re-
search, business and health care, namely: (1) donors of
biological materials, (2) clinicians providing patient re-
cords, (3) laboratory units collecting the samples, (4) stor-
age units, (5) research analysing the collections and
creating new diagnostic and drug targets, (6) patenting in-
stitutions, (7) health care industry, (8) patient cohorts, (9)
groups at risk, (10) general population and (11) educators.
Medical (patient) records as the central task for integrative
bioinformatics
How can integrative analytical data in the above-delineated
context and for the listed purposes be treated? A creation
of innovative medical records is considered as a priority
for scientific, coordinated and implementation-oriented
programmes of multidisciplinary character. Further, cre-
ation of innovative medical records might be a strong
driver for standardising communications in the broader
health-related scientific community and health care indus-
try [4,20,32]. However, with the exponential growth of
published descriptive knowledge, on one hand, and the
deluge of high-throughput data generated by advanced
technologies, on the other hand, there is a strong need for
strategies to manage, analyse and interpret the huge
amounts of data generated by different research disci-
plines and clinical fields relevant for predictive diagnostics,
targeted prevention and treatments tailored to the person.
Hence, for successful translation of research findings into
clinical applications beneficial for patients, the data and
knowledge should be accessible to multiple research disci-
plines that collaborate together on a particular health-
related topic. For that, the generated data and knowledge
should be appropriately collected, managed and shared
amongst stakeholders. The information management
includes data across biological scales, from individual
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gans, clinical phenotypes to individual patient profiles.
The information stream includes all stakeholders from
translational medicine to decision-making clinicians and
treated patients.
The mission of integrative bioinformatics is to provide
technological tools enabling collaboration across medical
fields, scientific disciplines and geographical barriers in
order to fulfil the following tasks:
– Gathering of complex data received from emerging
technologies, such as medical imaging,
pharmacogenetics, clinical omics, pathology-specific
molecular patters, disease modelling and individual
patient profiles.
– Undertaking both retrospective and prospective
analyses of biodata, information and knowledge
related to the (epi-) genome and its links to disease
for translational medicine.
– Providing help with information and knowledge to
advance health-related sciences and to make health
care services more reliable.
– Analysing complex technological inputs for making
optimal clinical decisions.
– Learning from what has happened at the individual,
process and health system levels to promote the
integrative approach by predictive, preventive and
personalised medicine (PPPM).
– Creating patient records and securing safety
treatment of patient databases.
– Promoting standardisation in health care.
– Presenting integrated data innovatively to enhance
comprehension.
Management of the sensitive ethical aspects linked to the
patient records
From what was mentioned previously, it is getting clear
that the innovative technologies of multidisciplinary
analysis summarised by comprehensive patient records
provide the complete information about individual health-
and pathology-specific profiles as well as about potential
disease predispositions of the individual. Therefore, the
concomitant professional activities should be dedicated to
the ethical issues, namely
– Secure the rights of the patient.
– Secure the strict control over but also the rights of
the specialised PPPM centres.
– Clearly define the authorisation to access individual
records in the database.
– Clearly define the authorisation to interpret
individual data.
– Secure and guarantee the access to the database for
authorised professionals only.– Regularly analyse potential long-term consequences
of the recorded data: health benefits for patients
versus potential danger of data misuse and wrong
interpretation.
– If necessary, revise the juristic platform to satisfy the
needs of patients properly.
A high quality of ethical standards is the prerequisite
for the successful implementation of PPPM in health care
systems [20,33].
Advancing ‘participatory medicine’: effective promotion of
health knowledge and health language in the general
population and collaboration with organised patient groups
‘Nothing about me without me’ is an excellent slogan of
the Society of Participatory Medicine [34] which certainly
should be broadly accepted by advanced medical services.
A number of independent evidence-based studies have
demonstrated that the efficacy of treatments strongly
depends on the level of harmony in ‘doctor-patient’
collaboration. In order to create the optimal condition
for the doctor-patient collaboration, a common language
should be used. For that high didactic quality educational
measures aiming at significant improvements of health
knowledge and health language in the general population
are strongly recommended. Unfortunately, information re-
trieved from the Internet is frequently of poor professional
quality providing controversial data that confuse the
understanding and slow down the learning process of
laymen. People need to be advised of reliable information
sources that are well adapted to a corresponding level of
understanding (categories of children, youth and adults)
and concrete interests of subpopulations (level of educa-
tion, groups of professionals, patient cohorts). In the field
of education, up-to-date information should be accessible
to and understandable for the layman on valid predictive
and prognostic tests and recommended specialists to be
consulted regarding the test interpretation for individual
health and disease conditions as well as creation of
consequent treatments tailored to the person. These
innovations along with the tight collaboration of organised
patient groups are one of the strongest instruments of a
more effective knowledge promotion [5].
A new professional environment needs a new culture of
communication of stakeholders for the successful realisation
of predictive, preventive and personalised medicine
Taking into account the challenges of current health care
systems and paradigm shift from reactive to predictive
medicine, a new professional environment should be
created to promote research in innovative bio/medical
fields and implementation of PPPM in health care. For
that, a new professional set-up is needed. However, for
their daily communication, different professional groups
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consequence of the ‘classical’ domain-relevant education
less understandable for others. This frequently leads to
misunderstandings when a great innovation proposed by
one professional group is underestimated (or even not
valued) by the others, resulting in delays in the imple-
mentation across diverse areas in predictive, preventive
and personalised medicine. Breaking such communication
barriers is a great challenge which can be solved only by
international and multidisciplinary networking providing
the necessary environment for a creation of multifaceted
didactic materials, new programmes specialised in multi-
disciplinary education and, finally, a new culture of
communication of PPPM stakeholders. Herewith, the
authors present a consolidated position to the point
made as follows: the innovative PPPM-related multi-
disciplinary educational programmes for professionals
should be prioritised in the New European Framework
Programme Horizon 2020 as well as by other global
and topic-relevant national programmes [4].
In order to promote a new culture of communication
of stakeholders in PPPM, worldwide pioneer initiatives
have been developed by The EPMA Journal focusing on
multidisciplinary research in traditional and innovative
medical fields. In particular, since 2010 the journal regularly
updates both needs and achievements in the field of PPPM
applied to common and rare diseases [35]. The following
topics are treated by the journal:
– Health care overview in European countries and
worldwide.
– New guidelines in health care.
– PPPM applied to chronic non-communicable
diseases (diabetes mellitus, cardiovascular disease,
cancer and neurodegenerative disorders and others).
– PPPM in rare diseases.
– PPPM in dentistry.
– Predictive medicine in groups at risk.
– Reproductive medicine.
– PPPM in pregnancy, neonatology and paediatrics.
– Body culture, individualised exercise training.
– Nutritional aspects in PPPM.
– Healthy ageing.
– Evidence-based traditional and alternative medicine.
– Integrative bioinformatics, patient records and
disease modelling.
– Treatments tailored to the person.
– Innovative drug delivery systems and new therapies.
– Validation of biomarkers.
– Standardisation of innovative biomedical approaches.
– Economic, ethical, legal, social and other relevant
aspects of PPPM.
– Collaboration strategies of professional groups with
complementary expertise.EPMA recommendations
General report and recommendations in PPPM
EPMA has released the package of recommendations for
their consideration by research units, educators, health care
industry, policymakers, and funding bodies to cover current
knowledge deficits in the field and to introduce integrative
approaches for advanced diagnostics, targeted prevention,
treatments tailored to the person and cost-effective health
care. This fundamental document has been published as
the EPMA White paper—see Figure 24 [5].
Consolidation of professional groups involved in
PPPM-relevant research and health care services
Status quo
Currently, any multidisciplinary meeting and collaboration
of professional groups related to health care usually are
results of an enthusiastic initiative of single groups who
realise that a multidisciplinary consolidation is the only
way on how to advance actual knowledge and services.
Recommended approach
Consolidation of professional groups involved in PPPM-
related research and health care services is a multifunc-
tional task which should be performed at several levels
of activities:
– Mandated optimal set-up of multidisciplinary
stakeholders in diagnostics and in the prevention
and treatment of individual pathologies.
– Regular meetings of stakeholders with multidisciplinary
expertise motivated and regulated by health
care-related national and international programmes.
– Multidisciplinary education as an obligation for
related professional groups.
– Creation of optimal economic conditions motivating
a multidisciplinary expertise to be applied in health
care sciences and services.
Essential measures to implement PPPM concepts
A ‘trans-disciplinary’ coordinating and networking action is
recommended
Implementation of the innovative PPPM concepts in
health care is a 3-dimensional challenge necessitating
1. International coordination, networking and
dissemination as a global approach for combating major
pathologies and improving economy of health care.
2. Coordination, networking and dissemination for
more effective treatment of collateral pathologies
(e.g. frequent cardiovascular complications occur in
patients with a history of diabetes).
3. Coordination, networking and dissemination among
stakeholders (individual professional groups involved
in disease-related science and management).
Figure 24 Recommendations in PPPM. ‘Recommendations in PPPM’ is the collective product of world-leading experts working in the branches
of PPPM under coordination of EPMA. The general report has been prepared as the consortial document proposed at the EPMA World Congress
2011 which took place in Bonn, Germany. This forum has analysed overall deficits and trends relevant for the top-science and daily practice in
PPPM focused on the patient.
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work and transparency of the action, individual profes-
sional domains may be grouped into two categories of
primary expertise (individual domains): (A) ‘General ’
and (B) ‘Technological tools’.
A. General domains represent following professional
groups and activities: Development of PPPM concepts in
health care, Integrative Bioinformatics, Translational
Medicine, Traditional, Complementary and Alternative
Medicine, TCAM, Health care economy, Medical Ethics,
Evidence-based assessment of health, Food, Well-being,
Professional integration in personalised medicine, Integra-
tive Education in PPPM, Promotion of young professionals,
Creation of innovative PPPM-relevant programmes for
research and implementation, Dissemination.
B. Technological tools are specialised professional
activities in Laboratory Medicine, Medical Imaging, Pre-
dictive Diagnostics, Biopreservation and Biobanking,
Disease Modelling, and Patient Profiling, Targeted Pre-
vention, Gender Medicine, Clustering of Specialised
Centres, Validation and Standardisation, Patenting and
Industrial Products, Evaluation of Clinical Application.
A synthesis of professional domains is highly recom-
mended as the trans-domain action to address current
deficits in PPPM-relevant professional knowledge and
health care. For that, well-designed coordinating measures,
data dissemination and networking among bio/medical
scientists, research centres, health care providers, industrial
partners, educators, patient organisations, policymakers,regulatory, funding and publishing bodies, and the public
domain are essential to be performed according to the
general scheme shown in Figure 25.
Integrative education is highly recommended for
PPPM specialists
The coordination in ‘Integrative Education in PPPM’ should
foresee following measures:
 A deep analysis of current barriers and actions
needed to implement multidisciplinary programmes
in PPPM, taking into account the existence of
specific directives for medical education and the
short list of recognised medical specialties.
 A consequent creation of the PPPM-specific
‘Communication Units’ to analyse the deficits in
multidisciplinary communication and to coordinate
the measures aimed at addressing these deficits, both
in the short-term (bridging the acute interdisciplinary
communication) and in the long-term (information
output for educational programmes) ones.
 Recruiting PPPM multidisciplinary taxonomy for
educational purposes.
 Elaboration of the didactic approach and
recommendations for preparing a series of ‘White
papers’ and ‘Position papers’ dedicated to the
innovative concepts of PPPM and input to
standardisation bodies, policymakers, regulators
and users.
Figure 25 General scheme recommended for the implementation in the trans-disciplinary-action. Main deliverable and health care-relevant
impacts are summarised utilising the synthesised PPPM expertise of individual domains relevant for predictive, preventive and personalised medicine
in health care.
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professionals to identify main concepts and
competence frameworks bridging separate fields of
science/disciplines to achieve breakthroughs that
require an interdisciplinary approach.
 Describing technological scenarios for learning that
might be useful to build spaces where knowledge
can be constructed collaboratively.
 Based on the experience from the performance of
the above measures, a creation of new well-designed
university curricula on PPPM.
Standardisation of health care services in Europe:
how to proceed
This is a strategic issue for policymakers after de-
tailed consultations with the relevant health care pro-
fessionals. In order to effectively promote advanced
medical services, much more harmonisation among
stakeholders is needed across the Europe. The process
of harmonisation requires clear focuses and should
result in reasonable standards introduced for com-
parable/analogous functional elements and systems.
All of the existing systems should be carefully ana-
lysed at the European level before corresponding stan-
dards may be elaborated and introduced in daily medical
practice.The European standards recommended by experts, in
particular, for analytical systems are as follows [20]:
 Consistent standards of laboratory (any other
analytical) practice.
 Conformance with all relevant international
standard systems.
 Equivalent units of measurement.
 Traceability of the measures.
 Equal quality of measurements.
 Equal reference systems.
 Equal evaluation systems.
The European standards recommended for the European
electronic patient record are as follows:
– Mandated multidisciplinary examination approach.
– Unified communication protocols for data exchange
between different information systems in health care.
– Consolidated algorithms.
– Standardised and complex interpretation of
analytical results.
It is obvious that these listed measures are tasks super-
ior to the national level. This may be effectively achieved,
if corresponding European resources will be adequately
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Summary and outlook
The new European programme Horizon 2020 is certainly
not a hype but a hope for the optimistic scenarios in
health care research and implementation, which Predict-
ive, Preventive and Personalised Medicine creates a robust
platform for. Horizon 2020 places to the disposal of
professionals the long-lasting instruments for scientific
and technological progress in medical services and health
care-related programmes. However, the overall success of
the programme strongly depends on the effective commu-
nication and consolidation of all the stakeholders relevant
for PPPM research and implementation as well as the com-
munication quality between health care providers and pol-
icymakers followed by the most optimal political decision in
favour of an active PPPM realisation in health care sector.
Since 2008, EPMA considers acute problems in medical
sciences as well as the quality and management of medical
services challenging health care systems in Europe and
worldwide. The Association is focused on the creation of
the long-term strategies and professional consolidation to
promote PPPM-related innovation in research and health
care. Using a well-consolidated expertise, EPMA has con-
tributed with the evidence-based scientific PPPM protocols
to the contents of Horizon 2020—the facts that EPMA
members are much proud about. Consequently, a series of
the PPPM-relevant projects of the EPMA experts and our
partners in Europe and worldwide are currently under con-
sideration, preparation and submission procedure that
follows already the very first calls released by the EU Com-
mission within the Horizon 2020 for the years 2014–2015.
The projects are focused on the patients' needs, innovative
medical sciences, optimal health and disease management,
coordinating and networking measures, expert recommen-
dations for the relevant medical fields and optimal solutions
which have a potential to advance health care services if the
long-term strategies were to be effectively implemented as
elaborated and published in the scientific works and funda-
mental documents of the EPMA consortia.
Also in the future, EPMA will consequently follow the
fundamental principles of the Association such as the
full transparency of the global strategies, permanent infor-
mation stream towards the stakeholders and best possible
consolidation of the professionals in PPPM. Over the en-
tire lifetime of the Horizon 2020, EPMA will permanently
update the world with the regularly published position
paper which will inform about the PPPM-relevant projects
submitted and evaluated to the individual topics/call and
the European programme as a whole.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
OG, JK and VC have drafted the manuscript and circulated it with the
members of the Association in order to finalise the EPMA position. All
authors read and approved the final manuscript.Authors’ information
The article is published on behalf of the European Association for Predictive,
Preventive and Personalised Medicine and expresses the consolidated
position of the EPMA members and representatives.
Author details
1Department of Radiology, Rheinische Friedrich-Wilhelms-University of Bonn,
53105 Bonn, Germany. 2The European Association for Predictive, Preventive
and Personalised Medicine, 1150 Brussels, Belgium. 3Technology Centre
Academy of Sciences, Prague 165 02, Czech Republic. 4The European
Medical Association, 1160 Brussels, Belgium.
Received: 28 February 2014 Accepted: 17 March 2014
Published: 7 April 2014References
1. Advances in Predictive, Preventive and Personalised Medicine.
[http://www.springer.com/series/10051]
2. Golubnitschaja O: Time for new guidelines in advanced diabetes care:
paradigm change from delayed interventional approach to predictive,
preventive & personalized medicine. EPMA J 2010, 1:3–12.
3. Norstedt I: Horizon 2020: European perspectives in healthcare sciences
and implementation. EPMA J 2014, 5:A1.
4. Golubnitschaja O, Swanton C, Danesi R, Costigliola V: Promoting predictive,
preventive and personalised medicine: European event of global
importance. EPMA J 2011, 2:131–136.
5. Golubnitschaja O, Costigliola V, EPMA: General Report &
Recommendations in Predictive, Preventive and Personalised Medicine
2012: White Paper of the European Association for Predictive, Preventive
and Personalised Medicine. EPMA J 2012, 1(1):14.
6. EPMA Summit and World Congress 2013 in Brussels: European
Association for Predictive, Preventive and Personalised Medicine
develops a new culture in communication amongst stakeholders. [http://
www.epmanet.eu/images/stories/pdfs/EPMA%20Summit%20and%20World%
20Congress%202013_press%20release_Oct%202013.pdf]
7. The EU Framework Programme for Research and Innovation - health,
demographic change and wellbeing. [http://ec.europa.eu/programmes/
horizon2020/en/h2020-section/health-demographic-change-and-wellbeing]
8. The EU Framework Programme for Research and Innovation - What is
Horizon 2010? [http://ec.europa.eu/programmes/horizon2020/en/what-
horizon-2020]
9. Innovation Unit - a Europe 2020 Initiative. [http://ec.europa.eu/research/
innovation-union/index_en.cfm]
10. Golubnitschaja O, Yeghiazaryan K: Opinion controversy to
chromium picolinate therapy's safety and efficacy: ignoring
“anecdotes” of case reports or recognising individual risks and
new guidelines urgency to introduce innovation by predictive
diagnostics? EPMA J 2012, 3:11.
11. Golubnitschaja O: Three levels of prediction, prevention & individualised
treatment algorithms to advance diabetes care: integrative approach. In
New Strategies to Advance Pre/Diabetes Care: Integrative Approach by PPPM.
Edited by Mozaffari MS. Dordrecht, Heidelberg, New York, London: Springer;
2013:15–28. ISBN 978-94-007-5970-1.
12. Golubnitschaja O: Diabetes mellitus. In Predictive Diagnostics and
Personalized Treatment: Dream or Reality?. Edited by Golubnitschaja O. New
York: Nova Science; 2009. 147–150, ISBN 978-1-60692-737-3.
13. Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M,
Kuhn W, Schild HH: Risk assessment, disease prevention and personalised
treatments in breast cancer: is clinically qualified integrative approach in
the horizon? EPMA J 2013, 4:6.
14. Golubnitschaja O, Yeghiazaryan K, Cebioglu M, Morelli M,
Herrera-Marschitz M: Birth asphyxia as the major complication in
newborns: moving towards improved individual outcomes by
prediction, targeted prevention and tailored medical care. EPMA J
2011, 2:197–210.
Golubnitschaja et al. The EPMA Journal 2014, 5:6 Page 29 of 29
http://www.epmajournal.com/content/5/1/615. Yeghiazaryan K, Flammer J, Golubnitschaja O: Predictive molecular
profiling in blood of healthy vasospastic individuals: clue to targeted
prevention as personalised medicine to effective costs. EPMA J 2010,
1:263–272.
16. Golubnitschaja O, Yeghiazaryan K, Flammer J: Key molecular pathways
affected by glaucoma pathology: is predictive diagnosis possible? EPMA
J 2010, 1:237–244.
17. Yeghiazaryan K, Flammer J, Golubnitschaja O: Individual predispositions in
healthy vasospastic individuals: patient profiling for targeted prevention
of “down-stream” pathologies as cost-effective personalised medicine. In
Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the
Future. Edited by Mandel S. Dordrecht, Heidelberg, New York, London:
Springer; 2013:13–29. ISBN 978-94-007-5865-0.
18. Golubnitschaja O, Yeghiazaryan K, Wunderlich K, Schild HH, Flammer J:
Disease proteomics reveals altered basic gene expression regulation in
leukocytes of normal-tension and primary open-angle glaucoma
patients. Proteomics Clin Appl 2007, 1:1316–1323.
19. Golubnitschaja O: Neurodegeneration: accelerated ageing or inadequate
healthcare? EPMA J 2010, 1:211–215.
20. Golubnitschaja O, Watson ID, Topic E, Sandberg S, Ferrari M, Costigliola V:
Position paper of the EPMA and EFLM: a global vision of the
consolidated promotion of an integrative medical approach to advance
health care. EPMA J 2013, 4:12.
21. HORIZON 2020 - WORK PROGRAMME 2014 – 2015. [http://ec.europa.eu/
research/participants/data/ref/h2020/wp/2014_2015/main/h2020-wp1415-
health_en.pdf]
22. Research & Innovation - Horizon 2020 Funding. [https://ec.europa.eu/
research/participants/portal/desktop/en/home.html]
23. Costigliola V, Gahan P, Golubnitschaja O: Predictive medicine as the new
philosophy in health care. In Predictive Diagnostics and Personalized
Treatment: Dream or Reality. Edited by Golubnitschaja O. New York: Nova
Science; 2009:1–3. ISBN 978-1-60692-737-3.
24. Golubnitschaja O: Changing long-held beliefs is never easy: a proposal
for multimodal approaches in female healthcare - an integrative view. In
Healthcare Overview: New Perspectives. Edited by Costigliola V. Dordrecht,
Heidelberg, New York, London: Springer; 2012:251–268.
ISBN 978-94-007-4602-2.
25. Costigliola V: Mobility of medical doctors as an attribute of the
cross-border healthcare: challenges, opportunities and perspectives. In
Healthcare Overview: New Perspectives. Edited by Costigliola V. Dordrecht,
Heidelberg, New York, London: Springer; 2012:233–244. ISBN
978-94-007-4602-2.
26. Carlsen S, Petersen PH, Skeie S, Skadberg Ø, Sandberg S: Within-subject
biological variation of glucose and HbA(1c) in healthy persons and in
type 1 diabetes patients. Clin Chem Lab Med 2011, 49:1501–1507.
27. Kapalla M, Matuskova D: Information systems as an essential component
of prediction in the laboratory diagnostics. In Predictive Diagnostics and
Personalized Treatment: Dream or Reality. Edited by Golubnitschaja O. New
York: Nova Science; 2009:529–548.
28. Mandel S, Golubnitschaja O: Time for new guidelines in handling of
neurodegenerative disorders: optimistic versus pessimistic prognosis by
application of PPPM. In Neurodegenerative Diseases: Integrative PPPM
Approach as the Medicine of the Future. Edited by Mandel S. Dordrecht,
Heidelberg, New York, London: Springer; 2013:3–9.
29. Shapira N: A gender-specific nutritional approach to women's healthcare.
In Healthcare Overview: New Perspectives. Edited by Costigliola V. Dordrecht,
Heidelberg, New York, London: Springer; 2012:269–305.
30. Marcus-Kalish M: Simultaneous systematic approach to enable predictive,
preventive and personalised medicine - women healthcare as a case
study. In Healthcare Overview: New Perspectives. Edited by Costigliola V.
Dordrecht, Heidelberg, New York, London: Springer; 2012:313–331.
31. Drucker E, Krapfenbauer K: Pitfalls and limitations in translation from
biomarker discovery to clinical utility in predictive and personalised
medicine. EPMA J 2013, 4:7.
32. Kapalla M: Healthcare information complexity and the role of informatics
in predictive, preventive and personalized medicine. In Personalisierte
Medizin. Edited by Niederlag W, Lemke HU, Golubnitschaja O, Rienhoff O.
Dresden: Health Academy; 2010:83–108.33. Gefenas E, Cekanauskaite A, Tuzaite E, Dranseika V, Characiejus D: New
Ethical Paradigm in Preventive, Predictive and Personalised Medicine. In
Healthcare Overview: New Perspectives. Edited by Costigliola V. Dordrecht,
Heidelberg, New York, London: Springer; 2012:471–484.
ISBN 978-94-007-4602-2.
34. Society for Participatory Medicine. [http://participatorymedicine.org/]
35. The EPMA Journal. [http://www.epmajournal.com/]
doi:10.1186/1878-5085-5-6
Cite this article as: Golubnitschaja et al.: Predictive, Preventive and
Personalised Medicine as the hardcore of ‘Horizon 2020’: EPMA position
paper. The EPMA Journal 2014 5:6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
